# Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

> **NCT04464980** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 1516 (actual)

## Conditions studied

- Opioid Use Disorder (OUD)

## Interventions

- **DRUG:** SL-BUP
- **DRUG:** XR-BUP
- **DRUG:** XR-NTX
- **BEHAVIORAL:** MM
- **BEHAVIORAL:** MMR
- **BEHAVIORAL:** MMD

## Key facts

- **NCT ID:** NCT04464980
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 1516 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464980, "Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04464980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*